| 15.84 0.83 (5.53%) | 09-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 22.42 |
1-year : | 27.33 |
| Resists | First : | 19.2 |
Second : | 23.39 |
| Pivot price | 17.88  |
|||
| Supports | First : | 12.4 |
Second : | 10.32 |
| MAs | MA(5) : | 15.73 |
MA(20) : | 17.89 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0.2 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 20.4 |
D(3) : | 15.9 |
| RSI | RSI(14): 46.7 |
|||
| 52-week | High : | 23.39 | Low : | 8.19 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ELOX ] has closed above bottom band by 20.3%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 16.51 - 16.63 | 16.63 - 16.72 |
| Low: | 14.51 - 14.62 | 14.62 - 14.71 |
| Close: | 15.68 - 15.87 | 15.87 - 16.01 |
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
Mon, 31 Aug 2026
Eloxx Pharmaceuticals, Inc. (OTC: ELOX) Share Price, ELOX Stock News, ELOX Share Price & Updates - Kalkine
Mon, 17 Aug 2026
Eloxx Pharmaceuticals, Inc. Common Stock (NASDAQ: ELOX) Stock Price, News & Analysis - kalkine.ca
Fri, 14 Aug 2026
Nantahala Capital discloses 9.91% Eloxx Pharmaceuticals (ELOX) ownership in Schedule 13G - Stock Titan
Fri, 14 Aug 2026
Eloxx Pharmaceuticals (ELOX) stake hits 9.99% for Samsara affiliate - Stock Titan
Wed, 12 Aug 2026
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire
Mon, 27 Jul 2026
abrdn Inc. (ELOX) discloses 400,000-share, 9.91% holding in Eloxx - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 931130 (%) |
| Held by Institutions | 26.2 (%) |
| Shares Short | 8 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 3.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.5 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 4.5 |
| PEG Ratio | 1.8 |
| Price to Book value | 1.37 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 16590 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|